Similarly, another Phase Ib trial is evaluating the effectiveness of combining a different PI3K/mTOR dual inhibitor (Samotolisib) with a CDK4/6 inhibitor (Abemaciclib) in multiple common cancers.19 By extrapolating the available literature, we believe the approach of using Palbociclib with Gedatolisib to prevent the emergence of resistance in breast cancer is hypothetically applicable to other cancers including CRC. This evidence concerns the gene PIK3CA and breast carcinoma.